drugset
Drugs / M72/AS01E
last change Jul 2026 re-read 3 minutes ago

M72/AS01E

also known as M72/AS01E-4

Vaccine

Investigated by
Gates Medical Research Institute · Wellcome Trust

Trials 1

today NCT04556981 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04556981 Nov 2020 → Aug 2022 HIV infectious disease Gates Medical Research Institute Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2026-07-16 Gates Medical Research Institute Gates Medical Research Institute and the Serum Institute of India Reach Agreement for the Manufacture of M72/AS01E Tuberculosis Vaccine Candidate, Pending Successful Phase 3 Outcomes gatesmri.org ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as M72/AS01E ClinicalTrials.gov intervention name — accepted as the source's own label NCT04556981 ↗
Known as M72/AS01E-4 “BACKGROUND: M72/AS01E-4 is a recombinant fusion protein vaccine candidate derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) and AS01E-4 adjuvant.” PMID 40614747 ↗ Jul 2025
Modality Vaccine “M72/AS01E-4 is a recombinant fusion protein vaccine candidate” PMID 40614747 ↗ Jul 2025
Route Intramuscular “Participants will receive an intramuscular dose of M72” NCT04556981 ↗